Flerie

In July, two warrants of series 2021/2025, issued within the framework of the incentive program adopted at the annual general meeting 2021, have been exercised for subscription of two new shares in Flerie. Flerie has thereafter carried out a reverse share split of 1:100, whereby one hundred (100) existing shares became one (1) share, with the record date 15 July 2024. The reverse share split was resolved by the extraordinary general meeting on 10 June 2024. Through the issue of two new shares and the subsequent reverse share split, the number of shares and votes in Flerie decreased by 7,728,574,192 from 7,806,640,598 to 78,066,406.

The ISIN code for Flerie's ordinary share is SE0022447348.

For more information:

Ted Fjällman, CEO of Flerie
E-mail: ir@flerie.com

This information is published in accordance with Chapter 4, Section 9 of the Swedish Financial Instruments Trading Act (1991:980). This information was submitted for publication on 31 July 2024, at 08:00 CEST.

Flerie in brief

Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie’s active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB’s ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com